Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations

Clinical Pharmacokinetics

Volumn 32, Issue 5, 1997, Pages 368-381

  Piscitelli, Stephen C ^a   Reiss, William G ^b   Figg, William D ^c   Petros, William P ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450; CYTOKINE; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PROTEINASE; TUMOR NECROSIS FACTOR;

ANALYTIC METHOD; ANTIBODY PRODUCTION; BIOASSAY; CELL PROLIFERATION; CROSS REACTION; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCOMPETENCE; INTERMETHOD COMPARISON; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0030980940     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732050-00003     Document Type: Review

References (79)

1. Thorpe R, Wadhwa M, Bird CR, et al. Detection and measurement of cytokines. Blood Rev 1992; 6: 133-48
2. Yamada T, Fujishima A, Kawahara K, et al. Importance of disulfide linkage for constructing the biologically active human interleukin-2. Arch Biochem Biophys 1987; 257: 194-9
3. 486IL-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84: 1765-74
4. Cannon JG, van der Meer JW, Kwiatkowski D, et al. Interleukin-1-beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 1988; 7: 457-67
5. Rossio JL, Rager HC, Goundry CS, et al. Cytokine testing in clinical trial monitoring. In: Rose NR, DeMarcario EC, Fahey JL, et al., editors. Manual of clinical laboratory immunology. 4th ed. Washington, DC: American Society for Microbiology, 1992: 942-7
6. Cairo MS, Suen Y, Sender L, et al. Circulating granulocyte colony-stimulating factor levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood 1992; 79: 1869-73
7. Huanmura T, Motoyoshi K, Yosha K, et al. Quantification and identification of human monocytic colony-stimulating factor in human serum by enzyme-linked immunosorbent assay. Blood 1988; 72: 886-92
8. Layton JE, Hockman H, Sheridan WP, et al. Evidence for a novel in vivo control mechanism for granulopoiesis: mature cell-regulated control for regulatory growth factor. Blood 1989; 74: 1303-7
9. Petros WP, Rabinowitz J, Stuart AR, et al. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 1992; 80: 1135-40
10. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718-22
11. Bukowski RM, Budd GT, Gibbons JA, et al. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 1994; 12: 97-106
12. Bonner JC, Brody AR. Cytokine-binding proteins in the lung. Am J Physiol 1995; 268: L869-78
13. Guillaume T, Sekhavat M, Rubinstein DB, et al. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in non-hematopoietic human malignant cell lines. Cancer Res 1993; 53: 3139-44
14. Davies DR, Wlodawer A. Cytokines and their receptor complexes. FASEB J 1995; 9: 50-6
15. Miyajima A, Mui ALF, Ogorochi T, et al. Receptors for granulocyte-macrophage colony-stimulating factor. Interleukin-3, and Interleukin-5. Blood 1993; 82: 1960-74
16. Clemens MJ, editor. Cytokines. Oxford: βios Scientific, 1991
17. Cosman D. The hematopoietic receptor superfamily. Cytokine 1993; 5: 9-106
18. Miyajima A, Kitamura T, Harada N, et al. Cytokine receptors and signal transduction. Annu Rev Immunol 1992; 10: 295-331
19. Dubois CM, Ruscetti FW, Stern EW, et al. Hematopoietic growth factors upregulate the p65 type II interleukin-1 receptor on bone marrow progenitor cells in vitro. Blood 1992; 80: 600-8
20. Jacobsen SEW, Ruscetti FW, Dubois CM, et al. Induction of colony-stimulating factor receptor expression on hematopoietic progenitor cells: proposed mechanism for growth factor synergism. Blood 1992; 89: 678-87
21. Montero-Julian FA, Klein B, Gautherot E, et al. Pharmacokinetic study of anti-interleukin-6 therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of antii-IL-6 antibodies. Blood 1995; 85: 917-24
22. Heaney ML, Golde DW. Soluble hormone receptors. Blood 1993; 82: 1945-8
23. Engelmann H, Novick D, Wallach D. Tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-6
24. Yasukawa K, Saito T, Fukunaga T, et al. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem 1990; 108: 673-6
25. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599-607
26. Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994; 84: 4078-87
27. Haas R, Gericke G, Witt B, et al. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol 1993; 21: 109-13
28. Petros WP, Rabinowitz J, Stuart AR, et al. Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantation. Exp Hematol 1994; 22: 582-6
29. Serum levels of stem cell factor are increased in asymptomatic human immunodeficiency virus-infected patients and are associated with prolonged survival. Blood 1995; 86: 243-9
30. Wagner DK, Kiwanuka J, Edwards BK, et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987; 5: 1262-74
31. Beguin Y, Yerna M, Loo M, et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin produclion. Br J Haematol 1992; 82: 648-53
32. Reibnegger G, Krainer M, Herold M, et al. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991; 51: 6250-3
33. Kacinski BM, Stanley ER, Carter D, et al. Circulating levels of CSF-1 a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys 1989; 17: 159-64
34. Porter DL, Goldberg MA. Regulation of erythropoietin production. Exp Heme 1993; 21: 399-404
35. Waage A, Steinshamn S. Cytokine mediators of septic infections in the normal and granulocytopenic host. Eur J Haematol 1993; 50: 243-9
36. Raziuddin S, Sheikha A, Abu-Eshy S, et al. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer 1994; 73: 2426-31
37. Rabinowitz J, Petros WP, Stuart AR, et al. Characterization of endogenous cytokine concentrations following high-dose chemotherapy with autologous bone marrow support. Blood 1993; 81: 2452-2459
38. Strietier RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6
39. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-92
40. Elkordy M, Crump M, Vredenburgh JJ, et al. A phase I trial of recombinant human interleukin-1b OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant. In press
41. Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76: 1933-40
42. Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990; 323: 86-90
43. Macdougall IC, Roberts DE, Coles GA, et al. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99-115
44. Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994; 27: 19-31
45. Bocci V, Carraro F, Zeuli M, et al. The lymphocyte route: VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients. Biotherapy 1993; 6: 73-7
46. Rosenfeld CS, Sulecki M, Evans C, et al. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 1991; 19: 273-77
47. O'Day SJ, Rabinowe SN, Neuberg D, et al. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood 1994; 83: 2707-14
48. Kearns CM, Wang WC, Stute N, et al. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 1993; 123: 471-9
49. Porchet HC, Le Cotonnee JY, Loumaye E. Clinical pharamcology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modelling after repeated subcutaneous administration. Fertil Steril 1994; 61: 687-95
50. Jusko WJ, Ko HC. Physiologic indirect response models charcaterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406-19
51. Piscitelli SC, Forrest A, Vogel S, et al. A novel PK/PD model for infused interleukin-2 in HIV-infected patients [abstract]. Clin Pharmacol Ther 1996; 60: 162
52. Mannering GJ, Renton KW, el Azhary R, et al. Effects of interferon-inducing agents on hepatic cytochrome P-450 drug metabolizing systems. Ann NY Acad Sci 1980; 350: 314-31
53. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-15
54. Renton KW, Knickle LC. Regulation of hepatic cytochrome P-450 during infectious disease. Can J Physiol Pharmacol 1990; 68: 777-81
55. Laio J, Reiss WG. Drug-cytokine interactions: focus on cyclosporine. Pharmacotherapy 1996; 16: 401-8
56. Fukuda Y, Ishida N, Noguchi T, et al. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P-450 IA1, IA2, IIIA in human hepatoma cells. Biochem Biophys Res Commun 1992; 184: 960-5
57. Parmentier JH, Kremers P, Ferrai L, et al. Repression of cytochrome P-450 by cytokines: IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes. Cell Biol Toxicol 1993; 9: 307-13
58. Sakai H, Okamoto T, Kikkawa Y. Suppression of hepatic drug metabolism by the interferon inducer, polyribionosinc acid: polyribocitidylic acid. J Pharmacol Exp Ther 1992; 263 (1): 381-6
59. Williams JF, William JB, Sinclair JF, et al. Effect of interleukin 6 on phenobarbital induction of cytochrome P-450IIB in cultured rat hepatocytes. Biochem Biophys Res Commun 1991; 178 (3): 1049-55
60. Barker CW, Fagan JB, Pasco DS. Interleukin-1beta suppresses the induction of P450IA1 and P450IA2 mRNAs in isolated hepatocytes. J Biol Chem 1992; 267: 8050-5
61. Ferrari L, Kremers P, Batt AM, et al. Differential effects of human recombinant interleukin-1beta on cytochrome P-450 dependent activities in cultured fetal rat hepatocytes. Drug Met Disp 1992; 20: 407-12
62. Reiners JJ, Cantu AR, Rupp TA. Coorinate modulation of murine hepatic xanthine oxidase activity and cytochrome P-450 system by interferons. J Interferon Res 1990; 10: 109-18
63. Wright K, Morgan ET. Regulation of cytochrome P450IIC12 expression by interleukin-1alpha, interleukin-6, and dexamethasone. Mol Pharmacol 1991; 39: 468-74
64. Craig PI, Mehta I, Murray M, et al. Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Mol Pharmacol 1990; 38: 313-8
65. Ansher SS, Puri RK, Thompson WC, et al. The effects of interleukin 2 and alpha-interferon administration on hepatic drug metabolism in mice. Cancer Res 1992; 52: 262-6
66. Chen YL, Florentin I, Batt AM, et al. Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases. Biochem Pharmacol 1992; 44: 137-48
67. Thal C, Kahwaji JE, Loeper J, et al. Administration of high doses of human recombinant interleukin-2 decreases the expression of several P-450 cytochromes in the rat. J Pharmacol Exp Ther 1994; 268: 515-521
68. Chen YL, Le Vraux V, Leneveu A, et al. Acute phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-60
69. Gidal BE, Reiss WG, Liao JS, et al. Changes in interleukin-6 concentrations following epilepsy surgery: potential influence on carbamazepine pharmacokinetics [letter]. Ann Pharmacother 1996; 30: 545-6
70. Niven RW, Whitcomb KL, Shaner L, et al. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 1995; 12: 1343-9
71. Halme M, Maasilta P, Repo H, et al. Inhaled recombinant interferon-gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int J Radiat Oncol Biol Phys 1995; 31: 93-101
72. Syed TA, Cheema KM, Kahlon BM, et al. Human leukocyte interferon-alpha in cream for treatment of genital herpes in Asian males: a placebo-controlled, double-blind study. Dermatology 1995; 191: 32-5
73. Schneider A, Grubert T, Kirchmayr R, et al. Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia. Arch Gynecol Obstet 1995; 256: 75-83
74. Short SM, Rubas W, Paasch BD, et al. Transport of biologically active interferon-gumma across human skin in vitro. Pharm Res 1995; 12: 1140-5
75. Maskin SL. Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol 1994; 112: 1145-6
76. Takaya T, Ikeda C, Imagawa N, et al. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor in beagle dogs. J Pharm Pharmacol 1995; 47: 474-8
77. Lachman LB, Shih LC, Rao XM, et al. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses 1995; 11: 921-32
78. Anderson PM. Hanson DC, Hasz DE, et al. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF, and interferon-gamma. Cytokine 1994; 6: 92-101
79. Wood R, Montoya JG, Kundu SK, et al. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type I infection: a phase I/II study. J Infect Dis 1993; 167: 519-25